Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

Figures & data

Table 1 Baseline Patient Features

Characteristics	Total Population N = 111	Negative Skin Prick Test N = 51	Positive Skin Prick Test N = 60	p
Female gender, N (%)	71 (63.96)	33 (64.71)	38 (63.33)	>0.9999
Male gender, N (%)	40 (36.04)	18 (35.29)	22 (36.67)	>0.9999
Age, median values (IQR), years	56.00 (43.00–65.00)	57.00 (49.00–67.00)	51.50 (42.25–62.75)	0.0729
Duration of asthma, median val. (IQR), years	18.0 (10.00–30.00)	14.00 (10.00–21.00)	24.50 (13.00–31.75)	0.0008
FEV1, median values (IQR), % predicted	61.00 (49.75–74.25)	66.00 (50.00–78.00)	59.00 (48.00–73.00)	0.3367
Blood eosinophils, median v. (IQR), cells/μL	740.0(200.0–1097)	750.0 (550.0–1100)	700.0 (452.5–1010)	0.5987
Blood basophils, median val. (IQR), cells/μL	44.0 (30.00–86.00)	40.00 (20.00–65.00)	46.00 (30.00–90.00)	0.7328
BMI, median values (IQR), kg/m^2	26.17 (23.14–28.13)	25.21 (22.84–27.76)	27.02 (23.82–28.82)	0.0846
Smokers, N (%)	32 (28.83)	13 (25.49)	19 (31.67)	0.5321
Gastro-esophageal reflux disease, N (%)	55 (49.55)	24 (47.06)	31 (51.67)	0.7045
Nasal polyposis, N (%)	51 (45.95)	27 (52.94)	24 (40.00)	0.1867
Bronchiectasis, N (%)	27 (24.32)	12 (23.53)	15 (25.00)	>0.9999
Osteoporosis, N (%)	27 (24.32)	12 (23.53)	15 (25.00)	>0.9999
Anxiety, N (%)	21 (18.92)	11 (21.57)	10 (16.67)	0.6289
Atopic dermatitis, N (%)	13 (11.71)	1 (1.96)	12 (20.00)	0.0029
Obstructive sleep apnea syndrome, N (%)	11 (9.91)	3 (5.88)	8 (13.33)	0.2204

Note: Bold entries highlight statistically significant differences between patients with negative SPT versus subjects with positive SPT.

Figure 1 Efficacy of benralizumab in the whole population of patients with severe persistent eosinophilic asthma, with regard to asthma exacerbation rate (A), prednisone intake (B), daily SABA inhalations (C), ACT score (D), AQLQ score (E), FEV₁ (F), FVC (G), blood eosinophil numbers (H), blood basophil count (I), and FeNO levels (J). ACT score values are expressed as mean (± SD). All other parameters are expressed as median values (IQR). **p < 0.01; ***p < 0.001; ****p < 0.0001.

Figure 2 Efficacy of benralizumab in relation to SPT negativity or positivity, with regard to asthma exacerbation rate (A), prednisone intake (B), daily SABA inhalations (C), ACT score (D), AQLQ score (E), FEV₁ (F), FVC (G), blood eosinophil numbers (H), blood basophil count (I), and FeNO levels (J). Boxes display median values and IQR, and whiskers define maximum and minimum. *p < 0.05; **p < 0.01.

Figure 3 Correlations between serum IgE concentrations, expressed as logarithmic transformation, and 6-month modifications elicited by benralizumab, with regard to asthma exacerbation rate (A), prednisone intake (B), daily SABA inhalations (C), ACT score (D), AQLQ score (E), FEV₁ (F), FVC (G), blood eosinophil numbers (H), blood basophil count (I), and FeNO levels (J).